NZ601125A - Antibody formulation and therapeutic regimens - Google Patents
Antibody formulation and therapeutic regimensInfo
- Publication number
- NZ601125A NZ601125A NZ601125A NZ60112511A NZ601125A NZ 601125 A NZ601125 A NZ 601125A NZ 601125 A NZ601125 A NZ 601125A NZ 60112511 A NZ60112511 A NZ 60112511A NZ 601125 A NZ601125 A NZ 601125A
- Authority
- NZ
- New Zealand
- Prior art keywords
- seq
- formulation
- antibody
- heavy chain
- light chain
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 5
- 238000011285 therapeutic regimen Methods 0.000 title 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 abstract 2
- 235000013922 glutamic acid Nutrition 0.000 abstract 2
- 239000004220 glutamic acid Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 abstract 1
- 101001019598 Homo sapiens Interleukin-17 receptor A Proteins 0.000 abstract 1
- 229920001213 Polysorbate 20 Polymers 0.000 abstract 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 abstract 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 239000000872 buffer Substances 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 abstract 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 abstract 1
- 229940068977 polysorbate 20 Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Transplantation (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29538710P | 2010-01-15 | 2010-01-15 | |
| US42205910P | 2010-12-10 | 2010-12-10 | |
| PCT/US2011/020985 WO2011088120A1 (en) | 2010-01-15 | 2011-01-12 | Antibody formulation and therapeutic regimens |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ601125A true NZ601125A (en) | 2014-08-29 |
Family
ID=43858045
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ601125A NZ601125A (en) | 2010-01-15 | 2011-01-12 | Antibody formulation and therapeutic regimens |
Country Status (38)
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7833527B2 (en) | 2006-10-02 | 2010-11-16 | Amgen Inc. | Methods of treating psoriasis using IL-17 Receptor A antibodies |
| JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
| IN2012DN06720A (OSRAM) * | 2010-01-15 | 2015-10-23 | Kirin Amgen Inc | |
| CA2788863C (en) | 2010-02-04 | 2020-07-07 | Reinhard Franz Bolli | Immunoglobulin preparation |
| KR20130080790A (ko) | 2010-05-20 | 2013-07-15 | 아블린쓰 엔.브이. | Ｈｅｒ３와 관련된 생물학적 물질들 |
| WO2012040518A2 (en) | 2010-09-22 | 2012-03-29 | Amgen Inc. | Carrier immunoglobulins and uses thereof |
| CA2832556A1 (en) * | 2011-04-07 | 2012-10-11 | Glaxosmithkline Llc | Formulations with reduced viscosity |
| UA117218C2 (uk) | 2011-05-05 | 2018-07-10 | Мерк Патент Гмбх | Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f |
| JOP20200043A1 (ar) * | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
| US20140234330A1 (en) * | 2011-07-22 | 2014-08-21 | Amgen Inc. | Il-17 receptor a is required for il-17c biology |
| AU2012340621B2 (en) * | 2011-11-23 | 2017-10-12 | Amgen Inc. | Administration of alpha4beta7 hetero-dimer-specific antibody |
| ME02565B (me) * | 2012-03-07 | 2017-02-20 | Lilly Co Eli | Formulacija protutijela protiv il-17 |
| EP3184542A1 (en) | 2012-05-14 | 2017-06-28 | Novo Nordisk A/S | Stabilised protein solutions |
| NZ712294A (en) | 2013-03-15 | 2020-04-24 | Amgen Inc | Methods for treating crohn’s disease using an anti-il23 antibody |
| EP2968488A1 (en) | 2013-03-15 | 2016-01-20 | Amgen Inc. | Methods for treating psoriasis using an anti-il-23 antibody |
| JP6596014B2 (ja) * | 2014-03-31 | 2019-10-23 | アムジェン ケー・エー，インコーポレイテッド | 爪および頭皮乾癬の治療方法 |
| JP6671298B2 (ja) | 2014-05-16 | 2020-03-25 | アムジェン インコーポレイテッド | Ｔｈ１及びｔｈ２細胞集団を検出するためのアッセイ |
| SG11201701276SA (en) * | 2014-08-26 | 2017-03-30 | Kirin Amgen Inc | Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy |
| EP3193171B1 (en) * | 2014-09-10 | 2019-05-29 | NOF Corporation | Use of a protein adsorption inhibitor and method for inhibiting protein adsorption |
| AU2015357068B2 (en) | 2014-12-03 | 2021-07-29 | Csl Behring Ag | Pharmaceutical product with increased stability comprising immunoglobulins |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| KR20180063127A (ko) | 2015-09-17 | 2018-06-11 | 암젠 인크 | Il23 경로 바이오마커를 사용한, il23-길항제에 대한 임상 반응의 예측 |
| JP2018538249A (ja) | 2015-11-04 | 2018-12-27 | アストラゼネカ アクチボラグ | 好酸球性疾患における好酸球標的化治療薬に対する臨床応答の予測変数としてのジペプチジルペプチダーゼ−４およびペリオスチン |
| US11220541B2 (en) | 2015-12-22 | 2022-01-11 | Amgen Inc. | CCL20 as a predictor of clinical response to IL23-antagonists |
| EP3446178A4 (en) | 2016-04-19 | 2020-01-22 | Sage Electrochromics, Inc. | ELECTROCHROMIC DEVICE COMPRISING A TRANSPARENT CONDUCTIVE OXIDE LAYER AND AN OMNIBUS BAR AND ITS FORMING METHOD |
| GB201612043D0 (en) * | 2016-07-11 | 2016-08-24 | Crescendo Biologics Ltd | Composition for treatment of disorders |
| CA2974531A1 (en) * | 2017-07-26 | 2019-01-26 | Michael Giroux | Safety anchor and roof vent |
| GB201719447D0 (en) | 2017-11-23 | 2018-01-10 | Ucb Biopharma Sprl | Pharmaceutical composition |
| SG11202100185VA (en) | 2018-07-13 | 2021-02-25 | Astrazeneca Collaboration Ventures Llc | Treating ulcerative colitis with brazikumab |
| CN113474360B (zh) | 2019-02-18 | 2025-01-07 | 伊莱利利公司 | 治疗性抗体制剂 |
| WO2021050563A1 (en) * | 2019-09-09 | 2021-03-18 | The Rockefeller University | Antibody treatment for lesional tissue of hidradenitis suppurativa |
| CA3150951A1 (en) | 2019-09-11 | 2021-03-18 | Bausch Health Ireland Limited | Methods of treating nonalcoholic fatty liver disease (nafld) using il-17ra antibody |
| WO2021168100A1 (en) * | 2020-02-18 | 2021-08-26 | Amgen Inc. | Formulations of human anti-tslp antibodies and methods of using the same |
| CN112891531B (zh) * | 2020-06-19 | 2021-10-08 | 北京东方百泰生物科技股份有限公司 | 一种抗il-17ra单克隆抗体的注射制剂 |
| CA3218343A1 (en) * | 2021-05-12 | 2022-11-17 | Anaptysbio, Inc. | Antibody composition |
| WO2023240071A1 (en) * | 2022-06-06 | 2023-12-14 | Fusion Pharmaceuticals Inc. | Methods of dosing therapeutic agents |
Family Cites Families (99)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1000835A (en) | 1911-06-19 | 1911-08-15 | Stewart A Minnick | Calipers. |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| IL98078A0 (en) | 1991-05-07 | 1992-06-21 | Yeda Res & Dev | Pharmaceutical compositions comprising an anticytokyne |
| IL83878A (en) | 1987-09-13 | 1995-07-31 | Yeda Res & Dev | Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it |
| US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
| GB8807803D0 (en) | 1988-03-31 | 1988-05-05 | Glaxo Group Ltd | Biochemical product |
| AU631545B2 (en) | 1988-04-15 | 1992-12-03 | Protein Design Labs, Inc. | Il-2 receptor-specific chimeric antibodies |
| IL94039A (en) | 1989-08-06 | 2006-09-05 | Yeda Res & Dev | Antibodies to tbp - 1 and their use |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| DE59010941D1 (de) | 1989-04-21 | 2005-03-24 | Amgen Inc | TNF-Rezeptor, TNF bindende Proteine und dafür kodierende DNAs |
| DE3922089A1 (de) | 1989-05-09 | 1990-12-13 | Basf Ag | Neue proteine und ihre herstellung |
| ATE119942T1 (de) | 1989-05-18 | 1995-04-15 | Yeda Res & Dev | Tumor-nekrosefaktor-bindungsprotein ii, seine reinigung und spezifische antikörper. |
| IL95031A (en) | 1989-07-18 | 2007-03-08 | Amgen Inc | Method for the production of a human recombinant tumor necrosis factor inhibitor |
| US5703088A (en) | 1989-08-21 | 1997-12-30 | Beth Israel Deaconess Medical Center, Inc. | Topical application of spiperone or derivatives thereof for treatment of pathological conditions associated with immune responses |
| US5395760A (en) | 1989-09-05 | 1995-03-07 | Immunex Corporation | DNA encoding tumor necrosis factor-α and -β receptors |
| CA2065346C (en) | 1989-09-05 | 2005-03-29 | Craig A. Smith | Tumor necrosis factor-.alpha. and-.beta. receptors |
| ATE236249T1 (de) | 1989-09-12 | 2003-04-15 | Hoffmann La Roche | Tfn-bindende proteine |
| JPH03127800A (ja) | 1989-10-13 | 1991-05-30 | Teijin Ltd | 腫瘍壊死因子活性抑制物質 |
| DK0433900T3 (da) | 1989-12-13 | 1996-01-29 | Yeda Res & Dev | Ekspression af rekombinant tumornekrosefaktor bindingsprotein I (TBP-I) |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| DK0710719T3 (da) | 1990-01-12 | 2007-07-09 | Amgen Fremont Inc | Frembringelse af xenogene antistoffer |
| US5136021A (en) | 1990-02-27 | 1992-08-04 | Health Research, Inc. | TNF-inhibitory protein and a method of production |
| US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
| US6458360B1 (en) | 1990-04-25 | 2002-10-01 | The Johns Hopkins University | Soluble complement regulatory molecules |
| GB2243569A (en) | 1990-05-02 | 1991-11-06 | Andrew Langdon | Brush with timer |
| DE59109269D1 (de) | 1990-06-28 | 2005-12-15 | Hoechst Ag | Fusionsproteine mit Immunglobulinanteilen, ihre Herstellung und Verwendung |
| WO1992001002A1 (en) | 1990-07-11 | 1992-01-23 | Teijin Limited | Tumor necrosis factor activity inhibitor and production thereof |
| DK0567566T4 (da) | 1991-01-18 | 2007-10-22 | Amgen Inc | Fremgangsmåder til behandling af tumornekrosefaktor-medierede sygdomme |
| WO1992016221A1 (en) | 1991-03-15 | 1992-10-01 | Synergen, Inc. | Pegylation of polypeptides |
| IL99120A0 (en) | 1991-08-07 | 1992-07-15 | Yeda Res & Dev | Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them |
| JP3122139B2 (ja) | 1991-10-15 | 2001-01-09 | マラーキー，ミッシェル，エフ． | 後期段階炎症反応の治療用組成物 |
| US5716805A (en) | 1991-10-25 | 1998-02-10 | Immunex Corporation | Methods of preparing soluble, oligomeric proteins |
| ATE297465T1 (de) | 1991-11-25 | 2005-06-15 | Enzon Inc | Verfahren zur herstellung von multivalenten antigenbindenden proteinen |
| ATE242322T1 (de) | 1992-03-30 | 2003-06-15 | Immunex Corp | Fusionsprotein , das zwei rezeptoren des tumornekrose-faktors enthält |
| WO1993021946A1 (en) | 1992-04-30 | 1993-11-11 | Synergen, Inc. | Methods for treating interleukin-1 and tumor necrosis factor mediated diseases |
| JPH05312248A (ja) | 1992-05-08 | 1993-11-22 | Nissan Motor Co Ltd | シフトレバー装置 |
| KR100232688B1 (ko) | 1992-09-15 | 1999-12-01 | 스코트 쥐. 홀퀴스트 | 종양 괴사 인자 길항제를 함유하는 tnf-의존성 염증 치료용 제약 조성물 |
| DE69329974T2 (de) | 1992-12-04 | 2001-07-19 | Medical Research Council, London | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| US6562333B1 (en) | 1993-06-14 | 2003-05-13 | Schering Corporation | Purified mammalian CTLA-8 antigens and related reagents |
| WO1996029408A1 (en) | 1995-03-23 | 1996-09-26 | Immunex Corporation | Il-17 receptor |
| US6680057B1 (en) | 1995-03-23 | 2004-01-20 | Immunex Corporation | Methods of treating autoimmune disease by administering interleukin-17 receptor |
| WO1997004097A2 (en) | 1995-07-19 | 1997-02-06 | Genetics Institute, Inc. | Human ctla-8 and uses of ctla-8-related proteins |
| US6074849A (en) | 1995-07-19 | 2000-06-13 | Genetics Institute, Inc. | Polynucleotides encoding human CTLA-8 related proteins |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| TW555765B (en) | 1996-07-09 | 2003-10-01 | Amgen Inc | Low molecular weight soluble tumor necrosis factor type-I and type-II proteins |
| US6406867B1 (en) | 1996-08-16 | 2002-06-18 | Human Genome Sciences, Inc. | Antibody to human endokine alpha and methods of use |
| WO1998023284A1 (en) | 1996-11-27 | 1998-06-04 | Immunex Corporation | Method of regulating nitric oxide production |
| ATE549918T1 (de) | 1996-12-03 | 2012-04-15 | Amgen Fremont Inc | Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden |
| WO1999060127A2 (en) | 1998-05-15 | 1999-11-25 | Genentech, Inc. | Il-17 homologous polypeptides and therapeutic uses thereof |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| DE69841140D1 (de) | 1997-09-17 | 2009-10-22 | Human Genome Sciences Inc | Interleukin-17 rezeptor-ähnliches protein |
| US6482923B1 (en) | 1997-09-17 | 2002-11-19 | Human Genome Sciences, Inc. | Interleukin 17-like receptor protein |
| JP2000247903A (ja) * | 1999-03-01 | 2000-09-12 | Chugai Pharmaceut Co Ltd | 長期安定化製剤 |
| US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
| DE60044213D1 (de) | 1999-10-04 | 2010-05-27 | Novartis Vaccines & Diagnostic | Stabilisierte flüssige pharmazeutische Zusammensetzung enthaltend TFPI |
| US20020045213A1 (en) | 2000-03-16 | 2002-04-18 | Shuqian Jing | IL-17 receptor like molecules and uses thereof |
| TWI322154B (en) | 2000-03-16 | 2010-03-21 | Amgen Inc | Il-17 receptor like molecules and uses thereof |
| US20030180255A1 (en) | 2000-08-24 | 2003-09-25 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
| JP2004517918A (ja) | 2000-10-18 | 2004-06-17 | イミュネックス・コーポレーション | Ｉｌ−１７アンタゴニストを使用する慢性関節リューマチの治療法 |
| MXPA04008215A (es) | 2002-02-27 | 2004-11-26 | Immunex Corp | Formulacion polipeptidica. |
| US20050153880A1 (en) | 2002-06-27 | 2005-07-14 | Yukio Goto | Methods of treating or preventing ibd with il-18 |
| EP2366718A3 (en) | 2002-06-28 | 2012-05-02 | Domantis Limited | Ligand |
| DE10333317A1 (de) | 2003-07-22 | 2005-02-17 | Biotecon Therapeutics Gmbh | Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA) |
| CN1852711A (zh) | 2003-08-05 | 2006-10-25 | 3M创新有限公司 | 使用免疫响应调节化合物的传染病预防 |
| GB0321703D0 (en) * | 2003-09-16 | 2003-10-15 | Imerys Minerals Ltd | Surface modified fillers for polymer resin compositions |
| EP1712240B1 (en) | 2003-12-25 | 2015-09-09 | Kyowa Hakko Kirin Co., Ltd. | Stable water-based medicinal preparation containing antibody |
| IL159670A0 (en) | 2003-12-31 | 2004-06-01 | Yeda Res & Dev | Use of il-18 binding protein in inflammations |
| CN101014664B (zh) | 2004-06-04 | 2012-10-10 | 设计者分子公司 | 可自由基固化的聚酯及其使用方法 |
| GB0425569D0 (en) | 2004-11-19 | 2004-12-22 | Celltech R&D Ltd | Biological products |
| MX2007009810A (es) | 2005-02-14 | 2008-03-07 | Wyeth Corp | Uso de interleucina-17f en diagnostico y terapia de inflamacion de vias aereas. |
| CN101217979A (zh) | 2005-06-14 | 2008-07-09 | 安姆根有限公司 | 自缓冲蛋白制剂 |
| NZ599176A (en) | 2005-08-03 | 2014-04-30 | Immunogen Inc | Immunoconjugate formulations |
| US7790679B2 (en) | 2005-08-05 | 2010-09-07 | Amgen Inc. | Pharmaceutical formulations |
| CN101296706B (zh) | 2005-09-01 | 2011-11-30 | 先灵公司 | Il-23和il-17拮抗剂治疗自身免疫性眼部炎性疾病的用途 |
| US20070129302A1 (en) | 2005-10-18 | 2007-06-07 | Zeren Gao | Il-17c antagonists and methods of using the same |
| JP5555425B2 (ja) | 2005-11-01 | 2014-07-23 | ワイス・エルエルシー | 薬剤復元または希釈のための塩化ナトリウム溶液 |
| JP5231810B2 (ja) | 2005-12-28 | 2013-07-10 | 中外製薬株式会社 | 抗体含有安定化製剤 |
| JP2009525986A (ja) * | 2006-02-03 | 2009-07-16 | メディミューン，エルエルシー | タンパク質製剤 |
| CN101541833B (zh) * | 2006-10-02 | 2014-01-29 | 麒麟-安姆根有限公司 | Il-17受体a抗原结合蛋白质 |
| US7833527B2 (en) | 2006-10-02 | 2010-11-16 | Amgen Inc. | Methods of treating psoriasis using IL-17 Receptor A antibodies |
| WO2008049070A2 (en) | 2006-10-18 | 2008-04-24 | Zymogenetics, Inc. | Il-17c antagonists and methods of using the same |
| US20080213282A1 (en) * | 2006-12-21 | 2008-09-04 | Jaby Jacob | Formulations |
| FR2910324B1 (fr) | 2006-12-21 | 2009-03-06 | Biomerieux Sa | Nouveau medicament pour le traitement d'un cancer gastrique |
| GB0700523D0 (en) | 2007-01-11 | 2007-02-21 | Insense Ltd | The Stabilisation Of Proteins |
| MX2009010273A (es) | 2007-03-26 | 2009-10-12 | Zymogenetics Inc | Proteinas de fusion il-17ra/rc solubles y metodos relacionados. |
| CA2687720A1 (en) | 2007-06-13 | 2008-12-24 | Amgen Inc. | Il-17 heteromeric receptor complex |
| WO2009006301A2 (en) | 2007-06-29 | 2009-01-08 | Battelle Memorial Institute | Protein stabilization |
| JP2010536786A (ja) | 2007-08-17 | 2010-12-02 | アムジエン・インコーポレーテツド | ポリカチオンを用いた抗体およびｆｃ融合分子の製剤 |
| CA2715503C (en) | 2008-02-21 | 2016-08-09 | Amgen Inc. | Il-17ra-il-17rb antagonists and uses thereof |
| TW201117824A (en) | 2009-10-12 | 2011-06-01 | Amgen Inc | Use of IL-17 receptor a antigen binding proteins |
| IN2012DN06720A (OSRAM) | 2010-01-15 | 2015-10-23 | Kirin Amgen Inc | |
| EP2625199B1 (en) | 2010-10-08 | 2017-11-22 | Novartis AG | Methods of treating psoriasis using il-17 antagonists |
| EP3214442A1 (en) | 2010-10-25 | 2017-09-06 | F. Hoffmann-La Roche AG | Treatment of gastrointestinal inflammation and psoriasis and asthmainflammation and psoriasis a |
| CA2832556A1 (en) * | 2011-04-07 | 2012-10-11 | Glaxosmithkline Llc | Formulations with reduced viscosity |
| EA201391489A1 (ru) * | 2011-04-07 | 2014-02-28 | ГЛЭКСОСМИТКЛАЙН ЭлЭлСи | Композиции со сниженной вязкостью |
| US20140234330A1 (en) | 2011-07-22 | 2014-08-21 | Amgen Inc. | Il-17 receptor a is required for il-17c biology |
| JP6596014B2 (ja) | 2014-03-31 | 2019-10-23 | アムジェン ケー・エー，インコーポレイテッド | 爪および頭皮乾癬の治療方法 |
| SG11201701276SA (en) | 2014-08-26 | 2017-03-30 | Kirin Amgen Inc | Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy |
-
2011
- 2011-01-12 IN IN6720DEN2012 patent/IN2012DN06720A/en unknown
- 2011-01-12 JP JP2012549047A patent/JP5743234B2/ja active Active
- 2011-01-12 NZ NZ601125A patent/NZ601125A/en unknown
- 2011-01-12 HR HRP20171939TT patent/HRP20171939T1/hr unknown
- 2011-01-12 MX MX2012008213A patent/MX349856B/es active IP Right Grant
- 2011-01-12 AU AU2011205402A patent/AU2011205402B2/en active Active
- 2011-01-12 SI SI201131792T patent/SI3295957T1/sl unknown
- 2011-01-12 MY MYPI2016001562A patent/MY182680A/en unknown
- 2011-01-12 EP EP11705713.3A patent/EP2523688B1/en active Active
- 2011-01-12 LT LTEP11705713.3T patent/LT2523688T/lt unknown
- 2011-01-12 EA EA201891433A patent/EA201891433A3/ru unknown
- 2011-01-12 SI SI201131350T patent/SI2523688T1/en unknown
- 2011-01-12 PL PL17195530T patent/PL3295957T3/pl unknown
- 2011-01-12 HU HUE17195530A patent/HUE046670T2/hu unknown
- 2011-01-12 EP EP19189613.3A patent/EP3632466A1/en not_active Withdrawn
- 2011-01-12 EA EA201290653A patent/EA031209B9/ru not_active IP Right Cessation
- 2011-01-12 BR BR112012017150-0A patent/BR112012017150B1/pt active IP Right Grant
- 2011-01-12 PT PT171955305T patent/PT3295957T/pt unknown
- 2011-01-12 UA UAA201209849A patent/UA112288C2/uk unknown
- 2011-01-12 SG SG10201604093XA patent/SG10201604093XA/en unknown
- 2011-01-12 LT LTEP17195530.5T patent/LT3295957T/lt unknown
- 2011-01-12 MA MA35124A patent/MA33989B1/fr unknown
- 2011-01-12 DK DK17195530.5T patent/DK3295957T3/da active
- 2011-01-12 RS RS20191335A patent/RS59743B1/sr unknown
- 2011-01-12 RS RS20171311A patent/RS56781B1/sr unknown
- 2011-01-12 ES ES17195530T patent/ES2753216T3/es active Active
- 2011-01-12 US US13/521,999 patent/US8883151B2/en active Active
- 2011-01-12 PE PE2012001003A patent/PE20121691A1/es active IP Right Grant
- 2011-01-12 PT PT117057133T patent/PT2523688T/pt unknown
- 2011-01-12 KR KR1020127021299A patent/KR101766936B1/ko active Active
- 2011-01-12 ES ES11705713.3T patent/ES2652637T3/es active Active
- 2011-01-12 PH PH1/2012/501364A patent/PH12012501364A1/en unknown
- 2011-01-12 EP EP17195530.5A patent/EP3295957B1/en active Active
- 2011-01-12 CA CA2787128A patent/CA2787128C/en active Active
- 2011-01-12 SG SG2012051108A patent/SG182468A1/en unknown
- 2011-01-12 CN CN201180012846.1A patent/CN102821787B/zh active Active
- 2011-01-12 NO NO11705713A patent/NO2523688T3/no unknown
- 2011-01-12 DK DK11705713.3T patent/DK2523688T3/en active
- 2011-01-12 HU HUE11705713A patent/HUE035618T2/en unknown
- 2011-01-12 WO PCT/US2011/020985 patent/WO2011088120A1/en not_active Ceased
- 2011-01-12 PL PL11705713T patent/PL2523688T3/pl unknown
- 2011-01-14 AR ARP110100123A patent/AR079903A1/es not_active Application Discontinuation
- 2011-01-14 TW TW100101536A patent/TWI554282B/zh active
-
2012
- 2012-06-24 IL IL220602A patent/IL220602B/en active IP Right Grant
- 2012-06-26 TN TNP2012000335A patent/TN2012000335A1/en unknown
- 2012-07-11 ZA ZA2012/05167A patent/ZA201205167B/en unknown
- 2012-07-13 CL CL2012001966A patent/CL2012001966A1/es unknown
- 2012-08-10 CO CO12135074A patent/CO6640206A2/es unknown
- 2012-08-10 CR CR20120419A patent/CR20120419A/es unknown
-
2014
- 2014-09-29 US US14/499,691 patent/US10072085B2/en active Active
- 2014-12-05 JP JP2014247218A patent/JP2015052017A/ja active Pending
-
2015
- 2015-04-21 AU AU2015202023A patent/AU2015202023B2/en active Active
-
2017
- 2017-08-18 AU AU2017216579A patent/AU2017216579A1/en not_active Abandoned
-
2018
- 2018-01-09 CY CY20181100022T patent/CY1119852T1/el unknown
- 2018-08-02 US US16/053,564 patent/US10808033B2/en active Active
-
2019
- 2019-11-04 CY CY20191101143T patent/CY1122466T1/el unknown
-
2020
- 2020-09-08 US US17/015,029 patent/US11505612B2/en active Active
-
2022
- 2022-10-11 US US18/045,534 patent/US20230192873A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ601125A (en) | Antibody formulation and therapeutic regimens | |
| RU2486198C2 (ru) | Антиген, ассоциированный с ревматоидным артритом | |
| JP2013517277A5 (OSRAM) | ||
| PE20170687A1 (es) | Proteinas de enlace a cd127 | |
| AR080698A1 (es) | Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e | |
| RU2019113790A (ru) | Анти-lag-3 антитела и их композиции | |
| AR071891A1 (es) | Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano) | |
| AR081434A1 (es) | Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo | |
| HRP20140604T1 (hr) | Sredstva koja djeluju na cd138 i njihova upotreba | |
| PE20121579A1 (es) | Proteinas de enlace al antigeno il-23 humanas | |
| PE20241623A1 (es) | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos | |
| NZ602892A (en) | Antibodies that bind human cd27 and uses thereof | |
| RU2013143358A (ru) | Анти-fgfr4 антитела и способы их применения | |
| RU2015107889A (ru) | Композиция, содержащая два антитела, сконструированных так, чтобы они обладали пониженной и повышенной эффекторной функцией | |
| HRP20191678T1 (hr) | Pd-1 protutijelo, njegov fragment koji se veže na antigen, i njegova medicinska primjena | |
| NZ600768A (en) | Human antibodies to human angiopoietin-like protein 4 | |
| RU2014120629A (ru) | Антиген-связывающий белок и его применение в качестве продукта для адресной доставки при лечении рака | |
| PE20142243A1 (es) | Anticuerpos que se unen a ox40 y sus usos | |
| PE20160653A1 (es) | Proteinas de union a il-17 | |
| JP2014524748A5 (OSRAM) | ||
| CO6230999A2 (es) | Anticuerpo anti-esclerostina | |
| NZ622583A (en) | Protein formulations and methods of making same | |
| PE20120622A1 (es) | Anticuerpos anti-vegf y sus usos | |
| RU2014109039A (ru) | Биспецифические антигенсвязывающие молекулы | |
| RU2011129204A (ru) | Антитела против ангиопоэтина-2 человека |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 JAN 2016 BY CPA GLOBAL Effective date: 20150306 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 JAN 2017 BY CPA GLOBAL Effective date: 20160405 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 JAN 2018 BY CPA GLOBAL Effective date: 20161202 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 JAN 2019 BY CPA GLOBAL Effective date: 20171130 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 JAN 2020 BY CPA GLOBAL Effective date: 20181129 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 JAN 2021 BY CPA GLOBAL Effective date: 20191205 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 JAN 2022 BY COMPUTER PACKAGES INC Effective date: 20201218 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 JAN 2023 BY COMPUTER PACKAGES INC Effective date: 20211217 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 JAN 2024 BY ZACCO DENMARK A/S Effective date: 20221115 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 JAN 2025 BY ZACCO DENMARK A/S Effective date: 20240111 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 JAN 2026 BY ZACCO DENMARK A/S Effective date: 20241115 |